Affordable Access

Access to the full text

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)

Authors
  • Costa, Rogério A.1, 2
  • Jorge, Rodrigo2
  • Calucci, Daniela1
  • Melo, Luiz A. S. Jr.1
  • Cardillo, José A.1
  • Scott, Ingrid U.3
  • 1 Hospital de Olhos de Araraquara, U.D.A.T. Macular Imaging & Treatment Division, Rua Padre Duarte 989 apto 172, Araraquara, SP, 14801-310, Brazil , Araraquara (Brazil)
  • 2 University of São Paulo, Retina and Vitreous Section, Department of Ophthalmology, School of Medicine of Ribeirão Preto, Ribeirão Preto, SP, Brazil , Ribeirão Preto (Brazil)
  • 3 Penn State College of Medicine, Departments of Ophthalmology and Health Evaluation Sciences, Hershey, PA, USA , Hershey (United States)
Type
Published Article
Journal
Graefe's Archive for Clinical and Experimental Ophthalmology
Publisher
Springer-Verlag
Publication Date
Feb 28, 2007
Volume
245
Issue
9
Pages
1273–1280
Identifiers
DOI: 10.1007/s00417-007-0557-x
Source
Springer Nature
Keywords
License
Yellow

Abstract

BackgroundA novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).MethodsA single-centre, prospective, open-label study of 11 patients with documented CNV progression after PDT treatment who underwent combined PDT and intravitreal injection of 1.5 mg of bevacizumab was undertaken. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications and changes in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and in fluorescein leakage from CNV were evaluated.ResultsThe mean (±SD) age of the 11 patients was 74 (±5) years. Seven eyes had been treated with one previous PDT session and four eyes had two previous PDT sessions. The mean baseline logMAR ETDRS BCVA was 1.031 (Snellen equivalent, 20/200−2). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA (Snellen equivalent) was 0.944 (20/160−2), 0.924 (20/160−1), 0.882 (20/160+1), and 0.933 (20/160−2), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P ≤ 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively. Fluorescein leakage from CNV was absent in all eyes at week 12. One additional treatment session was required in seven (63.6%) eyes at week 24 due to recurrent fluorescein leakage from CNV (“minimum” [<50% of the leaking area noted at baseline], n = 4; and “moderate” [>50% of the leaking area noted at baseline], n = 3). No progression of the neovascular lesion was observed at week 24. No safety issues were identified throughout the period of the study.ConclusionsThe overall changes in vision and fluorescein leakage from CNV throughout the study suggest that a possible synergistic effect may arise from the combination of intravitreal bevacizumab with verteporfin PDT for the treatment of neovascular AMD.

Report this publication

Statistics

Seen <100 times